OZEM ETF Profile

Family:	Roundhill Financial
Name:	Roundhill GLP-1 & Weight Loss ETF

Inception Date:	21-May-2024
Termination Date:
Investment Objective:	The Fund is an actively managed exchange-traded fund ("ETF") that pursues its investment objective by seeking to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss ("GLP-1 & Weight Loss Drugs"). The Fund will focus its investments in the securities of companies that are the acknowledged leaders in the development of GLP-1 & Weight Loss Drugs, which it defines as those companies that have GLP-1 & Weight Loss Drugs currently undergoing Phase I, Phase II, and/or Phase III of U.S. Food & Drug Administration ("FDA") clinical trials and in securities of companies with GLP-1 & Weight Loss Drugs that have been approved by the FDA ("GLP-1 & Weight Loss Companies"). The Fund will also only invest in those companies with a minimum market capitalization of 100 million and an average daily trading volume of 500,000. The Adviser rebalances the weighting of the companies comprising the Fund's portfolio on at least a quarterly basis. The Fund may invest in U.S. and non-U.S. companies (including through investments in depositary receipts) and small-, mid- and large-capitalization issuers.

Prospectus

Top 10 Holdings
Novo Nordisk A/S	NVO	18.4100%
Eli Lilly & Co	LLY	15.8600%
Zealand Pharma A/S	ZEAL	5.0000%
Roche Holding AG	ROG	4.9100%
Chugai Pharmaceutical Co Ltd	4519	4.2500%
AstraZeneca PLC	AZN	4.2400%
Innovent Biologics Inc	1801	3.7100%
Viking Therapeutics Inc	VKTX	3.5100%
Amgen Inc	AMGN	3.3900%
Altimmune Inc	ALT	3.3400%
	Top 10 Holdings Weight:	66.6%